Yahoo
NasdaqGS - Delayed Quote USD

GeneDx Holdings Corp. (WGS)

85.99 -1.40 (-1.60%)
At close: September 4 at 4:00:00 PM EDT
84.00 -1.99 (-2.31%)
After hours: September 4 at 7:30:04 PM EDT
Trade WGS on Coinbase
Chart Range Bar
Loading chart for WGS
  • Previous Close 87.39
  • Open 87.74
  • Bid 61.64 x 200
  • Ask 108.59 x 200
  • Day's Range 84.16 - 87.99
  • 52 Week Range 32.21 - 170.87
  • Volume 304,279
  • Avg. Volume 797,815
  • Market Cap (intraday) 2.564B
  • Beta (5Y Monthly) 2.01
  • PE Ratio (TTM) --
  • EPS (TTM) -3.58
  • Earnings Date (est.) Oct 27, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 90.44

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

www.genedx.com

1,300

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

WGS
33.88%
S&P 500 (^GSPC)
12.75%

1-Year Return

WGS
33.99%
S&P 500 (^GSPC)
18.71%

3-Year Return

WGS
1,813.01%
S&P 500 (^GSPC)
70.93%

5-Year Return

WGS
73.94%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 114.44M
Earnings -17.74M
Profit Margin -15.50%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-50M
0
50M
100M
-60.0%
-50.0%
-40.0%
-30.0%
-20.0%
-10.0%

Analyst Insights

View More

Analyst Price Targets

74.00 Low
90.44 Average
85.99 Current
103.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/4/2026
Analyst Canaccord Genuity
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 75 -> 90

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -23.41%

  • Return on Assets (ttm)

    -7.89%

  • Return on Equity (ttm)

    -40.80%

  • Revenue (ttm)

    454.43M

  • Net Income Avi to Common (ttm)

    -106.36M

  • Diluted EPS (ttm)

    -3.58

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    132.55M

  • Total Debt/Equity (mrq)

    68.54%

  • Levered Free Cash Flow (ttm)

    -47.5M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: